ERBB2 and breast cancer: In support of our findings, it is interesting to note that significantly higher methylation in IRF4 was previously observed in HER2+ breast tumors in relation to normal breast tissues [61], and that high IRF4 expression associates with improved outcome in HER2+ node-negative BC [62].